Advertisement

Neue Entwicklungen auf dem Gebiet der Diazepine

  • K.-H. Weber
Conference paper
  • 7 Downloads

Zusammenfassung

Vor 25 Jahren wurde Chlordiazepoxid (1)*), der erste Minortranquilizer aus der Reihe der 1,4-Benzodiazepine in die Therapie eingeführt [66]. Minor-Tranquilizer sind Pharmaka, die eine angstlösende, beruhigende und affektiv-entspannende Wirkung hervorrufen [4]. Heute kann als sicher angenommen werden, daß der Angriff der Benzodiazepine an spezifischen Rezeptoren erfolgt. Diese Benzodiazepinrezeptoren sind bei allen Vertebraten, auch beim Menschen [40] vorhanden und weisen für verschiedene Hirnregionen unterschiedliche Dichte auf [6]. Hohe Rezeptordichte finden wir beim Menschen insbesondere im zerebralen Cortex [6]. Durch die Wechselwirkung des Pharmakons, hier des Benzodiazepins, wird eine Kette von biochemischen Reaktionen ausgelöst an deren Ende der pharmakologische Effekt steht.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arbilla S (1985). Pharmacological profile of the imidazopyridine zolpidam at benzodiazepine receptors and electrocorticogram in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 330: 248PubMedCrossRefGoogle Scholar
  2. 2.
    Bechtel WD (1983). Pharmacokinetics and metabolism of brotizolam in humans. Br J Clin Pharmacol 16: 279Google Scholar
  3. 3.
    Bechtel WD (1985). Receptor Pharmacology. In: Nicholson AN, Welbers JB (eds) Sleep and Wake-fullness. Boehringer Ingelheim International GmbH PMS 3: 15Google Scholar
  4. 4.
    Benkert O, Hippius H (1974). Tranquilizer. In: Psychiatrische Pharmakotherapie, Springer, Berlin Heidelberg New York S 163Google Scholar
  5. 5.
    Bonetti EP, Pieri L, Cumin R, Schaffner R, Pieri M, Gamzu ER, Müller RKM, Haefely W (1982). Benzodiazepine antagonist Ro 15–1788; Neurological and behavioral effects. Psychopharmacology 78: 8–18Google Scholar
  6. 6.
    Braestrup C, Albrechtsen R, Squires RF (1977). High Densities of benzodiazepine receptors in human cortical areas. Nature 279: 702CrossRefGoogle Scholar
  7. 7.
    Braestrup C, Nielson M, Olsen CE (1980). Urinary and brain /3-Carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc Nat Acad Sci USA 77: 2288PubMedCrossRefGoogle Scholar
  8. 8.
    Braestrup C, Schmiechen R, Neef G, Nielson M, Petersen EN (1982). Interaction of convulsive li-gants with benzodiazepine receptors. Science 216: 2141CrossRefGoogle Scholar
  9. 9.
    Braestrup C (1984). Molecular interactions in the GABA/benzodiazepine receptor, chlorid channel complex. Clin Neuropharmacol 7 Suppl 1: 300Google Scholar
  10. 10.
    Breimer DD, Jochemsen R (1983). Clinical pharmacokinetics of hypnotic benzodiazepines: A summary. Br J Clin Pharmacol 16: 277S - 278SPubMedGoogle Scholar
  11. 11.
    Breimer DD (1985). Pharmaco Kinetics. In: Nicholson AN, Welbers JB (eds) Sleep and Wakefulness. Boehringer Ingelheim International GmbH PMS 4: 31Google Scholar
  12. 12.
    Casals-Stenzel J (1985). The inhibitory activity of brotizolam and related compounds on platelet activating faktor (PAF) induced effects in vitro and in vivo. Vortrag beim Intern Res Symp (PAF) Hilton Head Island, South Carolina USA am 15. -18. 10.Google Scholar
  13. 13.
    Casals-Stenzel J, Weber KH, Bechtel W: Poster ibid.Google Scholar
  14. 14.
    Chan CY, Gibbs ‘IT, Borden LA, Farb DH (1984). Multiple embryonic benzodiazepine binding sites: Evidence for functionality. Life Sci 33: 2061–2069Google Scholar
  15. 15.
    Chaudoir PJ, Jarvie NC, Wilcox GJ (1983). The acceptability of a non - benzodiazepine hypnotic ( Zopizolam) in general practice. J Int Med Res 11: 333Google Scholar
  16. 16.
    Chweh AY, Lin YB, Swinyard EA (1984). Hypnotic action of benzodiazepines: A possible mechanism. Life Sci 34: 1763–1768Google Scholar
  17. 17.
    Danneberg P, Weber KH (1983). Chemical structure and biological activity of the diazepines. Br J Clin Pharmacol 16: 231S - 243SPubMedGoogle Scholar
  18. 18.
    Dawson GW, Jue SG, Brogden RN (1984). Alprazolam: A review of its pharmacodynamic properties in the treatment of anxiety and depression. Drugs 27: 132–147Google Scholar
  19. 19.
    Dodd RH, Quannès C, Prado de Carvalho L, Valin A, Venault P, Chapouthier G, Rossier J, Potier P (1985). 3-Amino-ß-carboline derivates and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem 28: 824–828PubMedCrossRefGoogle Scholar
  20. 20.
    Draper RJ, Daly I (1983). Alprazolam and amitryptyline: A double blind comparison of anxiolytic and anti-dpressant activity. Irish Med J 76: 453Google Scholar
  21. 21.
    Drugs of the Future (1976). Alprazolam 1: 551Google Scholar
  22. 22.
    Drugs of the future (1980). 5:43Google Scholar
  23. 23.
    Ehlert FJ, Roeske WR, Gee KW, Yamamura HJ (1983). An allosteric model for benzodiazepine receptor function. Biochem Pharmacol 32: 2375–2383PubMedCrossRefGoogle Scholar
  24. 24.
    Feldon J, Lerner T, Levin D, Myslobodsky M (1983). A behavioral examination of convulsant benzodiazepine and GABA antagonist, Ro 5–3663, and benzodiazepinereceptor antagonist R 15–1788. Pharmacol Biochem Behav 19: 39–41PubMedCrossRefGoogle Scholar
  25. 25.
    Hamor TA, Martin IL (1983). The benzodiazepines. In: Ellis GP, West GB (eds) Proceedings in medicinal chemistry. Elsevier Science Publishers BV (Amsterdam, 20: 157–223 )Google Scholar
  26. 26.
    Hirose K, Matsushita A, Eigyo M, Jyoyama H, Fujita A, Tsukinoki Y, Shiomi T, Matsubara K (1981). Pharmacology of 2-o-chlorobenzoyl-4-chloro-N-methyl-N-alphaglycyl-glycinanilide Hydrate (45–0088-S), a compound with benzodiazepine-like properties. Arzneim Forsch 31: 63Google Scholar
  27. 27.
    Hock FJ, McGaugh JL (1985). Enhancing effects of Hoe 175 on memory in mice. Psychopharmacology 86: 144CrossRefGoogle Scholar
  28. 28.
    Hunkeler W, Möhler H, Pieri J, Pole P, Bonetti EP, Cumin R, Schaffner R, Hafely W (1981). Selevtive antagonistis of benzodiazepines. Nature 290: 514PubMedCrossRefGoogle Scholar
  29. 29.
    Klepner CA, Lippa AS, Benson DS, Sano MC, Beer B (1979). Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors. Pharmacol Biochem Behav 11: 457–462PubMedCrossRefGoogle Scholar
  30. 30.
    Kornecki E, Ehrlich YH, Lenox RH (1984). Plateletactivating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science 226: 1454–1456PubMedCrossRefGoogle Scholar
  31. 31.
    Krüger J, Müller-Limmroth W (1983). Residual effects of flurazepam and brotizolam on psychomotor performance. Br j Clin Pharmacol 16: 347S - 351SGoogle Scholar
  32. 32.
    Kyburz E (1981). New trends in minor tranquilizers. In: De Las Heras FG, Vega S (eds) Medicinal chemistry advances. Pergamon Press Oxford, 355–368Google Scholar
  33. 33.
    Lippa AS, Klepner CA, Yunger L, Sano MC, Smith WV, Beer B (1978). Relationship between benzodiazepine receptor and experimental anxiety in rats. Pharm Biochem Behav 9: 853–856CrossRefGoogle Scholar
  34. 34.
    Little HJ (1984). The effects of benzodiazepine agonists, inverse agonists and Ro 15–1788 on the responses of the superior cervical ganglion to GABA in vitro. Br J Pharmacol 83: 057–068Google Scholar
  35. 35.
    Lupolover R, Amrein R (1984). Review of Clinical investigations with the benzodiazepine antagonist Ro-15–1788. Clin Neuropharm 7 Suppl 1: 668Google Scholar
  36. 36.
    Marangos PJ, Patel J, Boulenger JP, Clark-Rosenberg R (1982). Characterization of peripheral-type benzodiazepine binding sites in brain using [3H1 Ro 5–4864. Mol Pharmacol 22: 26–32PubMedGoogle Scholar
  37. 37.
    Menini T, Barone D, Colombo A, Glasser A, Luzzani F (1984). In vitro interaction of premazepam with benzodiazepine receptors in rat brain regions. Life Sciences 35: 365–371CrossRefGoogle Scholar
  38. 38.
    Midazolam (1980). Arzneim Forsch 31 (12a) Symposium GenfGoogle Scholar
  39. 39.
    Möhler H, Okada T (1977). Properties of 3H-diazepam binding to benzodiazepine receptors in rat cerebral cortex. Life Sciences 20: 2101–2110PubMedCrossRefGoogle Scholar
  40. 40.
    Möhler H, Okada T (1978). Benzodiazepine receptors in normal and pathological human brain. Br J Psychiatry 133: 261PubMedCrossRefGoogle Scholar
  41. 41.
    Mohler H, Richards JG (1981). Agonist and antagonist benzodiazepine receptor interaction in vitro. Nature 294: 763PubMedCrossRefGoogle Scholar
  42. 42.
    Möhler H, Richards JG (1983). From molecular biology to clinical practice. In: Costa E (eds) The Benzodiazepines, Raven Press New YorkGoogle Scholar
  43. 43.
    Nakanishi M, Tahara T, Araki K, Shiroki M, Tsumagari T, Takigawa Y (1973). Synthesis and structure-activity relationships of 5-phenyl-1,3-dihydro-2H-thieno[2,3-e] [1,41diazepine-2-ones. J Med Chem 16: 214PubMedCrossRefGoogle Scholar
  44. 44.
    Nicholson AN (1983). Brotizolam: Review of clinical studies. Br J Pharmac 16: 433SGoogle Scholar
  45. 45.
    Niehoff DL, Mashal R, Kuhar M (1983). Benzodiazepine receptors: Preferential stimulation of type 1 receptors by pentobarbital. J Pharmacol 92: 131–134Google Scholar
  46. 46.
    Nielsen M, Braestrup C, Squires RF (1978). Evidence for a late evolutionary appearence of brain-specific benzodiazepine receptors: An investigation of 18 vertebrate and 5 invertebrate species. Brain Research 141: 342–346PubMedCrossRefGoogle Scholar
  47. 47.
    Paul SM, Syapin PJ, Paugh BA, Moncada V, Skolnick P (1979). Correlation between benzodiazepine receptor occupation and anticonvulsant effects of diazepam. Nature 281: 688PubMedCrossRefGoogle Scholar
  48. 48.
    Pharmacology (1984). 27 Suppl. 2Google Scholar
  49. 49.
    Pole P, Bonetti EP, Schaffner R, Haefely W (1982). A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15–1788, benzodiazepine tranquilizers, ß-carbolines, and phenobarbitone. Naunyn-Schmiedeberg’s Arch Pharmacol 321: 260–264CrossRefGoogle Scholar
  50. 50.
    Roehrs T. Zorick F. Koshorek GL, Wittig R, Roth T (1983). Effects of acute administration of brotizolam in subjects with disturbed sleep. Br J Clin Pharm 16: 371–376SGoogle Scholar
  51. 51.
    Römer D, Büscher HH, Hill PC, Maurer R, Petcher TJ (1982). An opioid benzodiazepine. Nature 298: 759PubMedCrossRefGoogle Scholar
  52. 52.
    Rossi S, Pirola O, Maggi R (1969). 1, 2, 4, 5-Tetrahydro-2,4-dioxo-3H-1,5-benzodiazepines. Chim. Ind (Milan) 51: 479Google Scholar
  53. 53.
    Ruhland M, Liepmann H, Muesch HR (1985). 1,2-Anellated 1,4-benzodiazepine derivatives a new class of antipsychotics. Pharmacopsychiatry 18: 174Google Scholar
  54. 54.
    Saletu B, Grünberger J, Linzmayer L (1983). Quantitative pharmaco-EEG and performance after administration of brotizolam to healthy volunteers. Br J Clin Pharmac 16: 333S - 345SGoogle Scholar
  55. 55.
    Sato T, Konishi M, Ago T, Nakagawa Y, Iwatani K, Mori (1980). Metabolism of peptido-aminobenzophenone (2-o-chlorbenzoyl-4-chloro-N-methyl-N’-glycil-glycinanilide) in Dogs. Xenobiotica 10: 125–133Google Scholar
  56. 56.
    Schmitt J, Comoy P, Suquet M, Boitard J, LeMeur J, Basselier JJ, Brunaud M, Salle J (1967). Sur un nouveau myorelaxant de la classe des benzodiazepines: Le tetrazepam. Chim Thérap 2: 254Google Scholar
  57. 57.
    Schoch P, Richards JG, Häring P, Takacs B, Stähli C, Staehelin T, Haefely W, Möhler H (1985). Co-localisation of GABAA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature 314: 168PubMedCrossRefGoogle Scholar
  58. 58.
    Schütz H (1982). Benzodiazepine-Entdeckung, Entwicklung and Zukunftsperspektiven. Pharmazie in unserer Zeit 11: 161PubMedCrossRefGoogle Scholar
  59. 59.
    Sethy VII, Hodges DH (1982). Role of ß-adrenergic receptors in the antidepressant activity of alprazolam. Res Comm Chem Pathol Pharmcol 36: 329Google Scholar
  60. 60.
    Skolnick P, Schweri MM, Williams EF, Moncada VY, Paul SM (1982). An in vitro binding assay which differentiates benzodiazepine agonists and antagonists. Eur J Pharmacol 78: 133–136PubMedCrossRefGoogle Scholar
  61. 61.
    Snyder F (1982). Platelet activating factor (PAF), A novel type of phospholipid with diverse biological properties. In Hess HJ (ed) Annual Reports in Medicinal Chemistry 17: 243–252Google Scholar
  62. 62.
    Squires RF, Braestrup C (1977). Benzodiazepine receptors in rat brain. Nature 266: 732–734PubMedCrossRefGoogle Scholar
  63. 63.
    Squires RF, Benson DI, Braestrup C, Coupet J, Klepner CA, Myers V, Beer B (1979). Some properties of brain specific benzodiazepine receptors: New evidence for multiple receptors. Pharm Biochem Behav 10: 825–830CrossRefGoogle Scholar
  64. 64.
    Stanski DR, Watkins WD (eds) (1982). Drug disposition in anesthesia. Grune and Straton, New York p 173–191Google Scholar
  65. 65.
    Sternbach LH, Fryer RJ, Keller O, Metlesics W, Sach G, Steiger N (1963). Quinazolines and 1,4benzodiazepines. Nitro-substituted 5-phenyl-1,4-benzodiazepine derivative. J Med Chem 6: 261PubMedCrossRefGoogle Scholar
  66. 66.
    Sternbach LH (1978). The benzodiazepine story. In: Jucker E (eds) Progress in Drug Research, p 229–266Google Scholar
  67. 67.
    Sternbach LH (1979). The benzodiazepine story. J Med Chem 22: 1–7PubMedCrossRefGoogle Scholar
  68. 68.
    Sternbach LH (1979). Chemistry of 1,4-benzodiazepine and some aspects of the structure-activity relationship. In: Carattini S, Mussini E, Randall LO (eds) The diazepines. Raven Press New York, p 17Google Scholar
  69. 69.
    Sugasawa T, Adachi M, Sasakura K, Matsushita A, Eigyo M, Shiomi T, Shintaku H, Takahara Y, Murata S (1985). 1-Azacycloalkyl-1–4-benzodiazepin-2-ones with antianxiety-antidepressant actions. J Med Chem 28: 699–707Google Scholar
  70. 70.
    Tanaka M, Mizuki Y, Isozaki H, Inanaga K (1983). Effect of zopiclone on the arousal level of healthy volunteers assessed by the averaged photopalpebral reflex. Eur J Clin Pharmacol 24: 469–474PubMedCrossRefGoogle Scholar
  71. 71.
    Ticku MK (1983). Benzodiazepine-GABA receptor-ionophore complex. Neuropharmacology 22: 1459–1470PubMedCrossRefGoogle Scholar
  72. 72.
    Triazolam (1981). Br J Clin Pharmacol 11: 1–120Google Scholar
  73. 73.
    Ventui MC (1985). Platelet-activating factor: Multifaceted biochemical and physiological mediator. In: Bailey DM (ed) Annual Reports in Medicinal Chemistry 20: 193–202Google Scholar
  74. 74.
    Wald de H, Nordin IC, L’italien VJ, Parcell RF (1973). Pyrazolodiazepines 1,3-(and 2,3-)dialkyl4,6-dihydro-8-ary1pyrazolo[4.3–41,4]diazepin-5-ones as antianxiety Agents. J Med Chem 16: 1346Google Scholar
  75. 75.
    Weber KH, Bauer A, Hauptmann KH (1972). N-Aryl-und N-Heteroaryl-1H-1,5-benzodiazepin2,4-[3H,5H]-dione. Liebigs Ann Chem 756: 128–138CrossRefGoogle Scholar
  76. 76.
    Weber KH (1985). Molecular development In: Nicholson AN, Welbers JB (eds) Sleep and wakefullness. Boehringer Ingelheim International GmbH PMS 3:1Google Scholar
  77. 77.
    Weber KH, Kuhn F, Böke-Kuhn K, Lehr E, Danneberg PB, Hommer D, Paul SM, Skolnick P (1985). Pharmacological and neurochemical properties of 1,4-diazepines with two annelated heterocycles („hetrazepines“). Eur J Pharmacol 109: 19–31PubMedCrossRefGoogle Scholar
  78. 78.
    Weismann BA, Cott J, Jackson JA, Bolger GT, Weber KH, Horst D, Paul SM, Skolnick P (1985). „Periphal-type“ binding sites for benzodiazepines in brain: Relationship to the convulsant actions of Ro 5–4864. J Neurochem 44: 1494Google Scholar
  79. 79.
    Wood PL, Loo P, Braunwalder A, Yokoyama N, Cheney L (1984). In vitro characterization of benzodiazepine receptor agonists, antagonists, inverse agonists and agonists/antagonists. J Pharmacol Exp Therap 231: 572Google Scholar
  80. 80.
    Zbinden G, Randall LO (1967). Pharmacology of benzodiazepines: Laboratory and clinical correlations. In: Garattini S, Shore PA (Eds) Advances in pharmacology. Academic Press New York London 5: 213–291Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1987

Authors and Affiliations

  • K.-H. Weber

There are no affiliations available

Personalised recommendations